Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...
Lilly inks gene therapy deal with Seamless Therapeutics to develop programmable recombinase treatments targeting genetic hearing loss worldwide.
Pharmaceutical Technology on MSN
Eli Lilly outlays $1.12BN for hearing loss gene therapy partnership
Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...
The market for microbiome sample preparation technology presents opportunities driven by demand for personalized medicine, ...
Seamless Therapeutics has received big pharma endorsement of its proprietary recombinase gene editing platform, sealing a potential $1.12 billion deal with Eli Lilly and Co. to apply the technology in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results